期刊
JOURNAL OF PSYCHIATRIC RESEARCH
卷 44, 期 15, 页码 1027-1034出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2010.03.011
关键词
Anorexia nervosa; Eating disorder; Atypical antipsychotics; Quetiapine; Pharmacotherapy
类别
资金
- Astra Zeneca Pty Ltd Australia
To investigate the safety and tolerability of the atypical antipsychotic quetiapine in anorexia nervosa patients and to determine the effect of quetiapine treatment on anorexic psychopathology and other key outcome measures including weight and body image we conducted a naturalistic open-label 12-week randomized controlled trial of low-dose (100-400 mg/day) quetiapine treatment versus treatment as usual in 33 anorexia nervosa patients from our Eating Disorder Clinics To monitor the effects of treatment over the medium term the participants were then followed up with assessment visits at 6 and 12 months after the end of the treatment phase Low-dose quetiapine treatment resulted in both psychological and physical improvements with minimal associated side-effects Given the overall trend toward improvement that we observed quetiapine appears to be a promising candidate for the treatment of anorexia nervosa Further large-scale placebo-controlled clinical trials will be necessary to fully evaluate the benefits of quetiapine treatment for this disorder (C) 2010 Elsevier Ltd All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据